Abstract
Abstract
Background
Primary hyperoxaluria is a genetic disorder of the metabolism of glyoxylate, the precursor of oxalate. It is characterized by high endogenous production and excessive urinary excretion of oxalate, resulting in the development of calcium oxalate nephrolithiasis, nephrocalcinosis, and, in severe cases, end-stage kidney disease and systemic oxalosis. Three different forms of primary hyperoxaluria are currently known, each characterized by a specific enzymatic defect: type 1 (PH1), type 2 (PH2), and type 3 (PH3). According to currently available epidemiological data, PH1 is by far the most common form (about 80% of cases), and is caused by a deficiency of the hepatic enzyme alanine:glyoxylate aminotransferase.
Methods
A survey on rare forms of nephrolithiasis and nephrocalcinosis with a focus on primary hyperoxaluria in the setting of Italian Nephrology and Dialysis Centers, using an online questionnaire, was recently conducted by the Project Group “Rare Forms of Nephrolithiasis and Nephrocalcinosis” of the Italian Society of Nephrology, with the aim of assessing the impact and management of this disorder in clinical practice in Italy.
Results
Forty-five public and private Italian Centers participated in the survey, and responses to the questionnaire were provided by 54 medical professionals. The survey results indicate that 21 out of the 45 participating Centers are managing or have managed primary hyperoxaluria patients, most of whom are on dialysis, or are recipients of kidney transplants.
Conclusions
The data of this survey indicate the need to implement genetic testing in suspected cases of primary hyperoxaluria, not only in the setting of dialysis or transplantation, but also with the aim of encouraging early diagnosis of PH1, which is the only type of primary hyperoxaluria for which specific drug therapy is currently available.
Graphical abstract
Funder
Alnylam Pharmaceuticals
Università Cattolica del Sacro Cuore
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Hoppe B (2012) An update on primary hyperoxaluria. Nat Rev Nephrol 8(8):467–475
2. Milliner DS, Harris PC, Sas DJ et al (2002) Primary hyperoxaluria type 1. [updated 2022 Feb 10]. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews® [Internet]. University of Washington, Seattle, pp 1993–2022 (PMID: 20301460)
3. Cregeen DP, Williams EL, Hulton S et al (2003) Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. Hum Mutat 22(6):497. https://doi.org/10.1002/humu.9200. (PMID: 14635115)
4. Ferraro PM, Unwin R, Bonny O, Gambaro G (2021) Practice patterns of kidney stone management across European and non European centers: an in depth investigation from the European Renal Stone Network (ERSN). J Nephrol. https://doi.org/10.1007/s40620-020-00854-6
5. Skolarikos A, Neisius A, Petřík A et al. European Association of Urology (EAU) Urolithiasis Guidelines. Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urolithiasis-2022_2022-03-24-142444_crip.pdf. Accessed 21 June 2023
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献